PT2877177T - Derivados do tipo azaindazole ou diazaindazole para tratamento da dor - Google Patents

Derivados do tipo azaindazole ou diazaindazole para tratamento da dor

Info

Publication number
PT2877177T
PT2877177T PT137458139T PT13745813T PT2877177T PT 2877177 T PT2877177 T PT 2877177T PT 137458139 T PT137458139 T PT 137458139T PT 13745813 T PT13745813 T PT 13745813T PT 2877177 T PT2877177 T PT 2877177T
Authority
PT
Portugal
Prior art keywords
azaindazole
derivatives
treating pain
diazaindazole
type
Prior art date
Application number
PT137458139T
Other languages
English (en)
Inventor
Sokoloff Pierre
Cachoux Frédéric
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of PT2877177T publication Critical patent/PT2877177T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PT137458139T 2012-07-27 2013-07-29 Derivados do tipo azaindazole ou diazaindazole para tratamento da dor PT2877177T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12305922.2A EP2689778A1 (en) 2012-07-27 2012-07-27 Derivatives of azaindoles or diazaindoles for treating pain

Publications (1)

Publication Number Publication Date
PT2877177T true PT2877177T (pt) 2017-02-06

Family

ID=48948392

Family Applications (1)

Application Number Title Priority Date Filing Date
PT137458139T PT2877177T (pt) 2012-07-27 2013-07-29 Derivados do tipo azaindazole ou diazaindazole para tratamento da dor

Country Status (29)

Country Link
US (1) US9381195B2 (pt)
EP (2) EP2689778A1 (pt)
JP (2) JP6456823B2 (pt)
KR (1) KR102120505B1 (pt)
CN (1) CN104684554B (pt)
AU (1) AU2013294920B2 (pt)
BR (1) BR112015001502B1 (pt)
CA (1) CA2879595C (pt)
CY (1) CY1118478T1 (pt)
DK (1) DK2877177T3 (pt)
ES (1) ES2612349T3 (pt)
HK (1) HK1207302A1 (pt)
HR (1) HRP20170104T1 (pt)
HU (1) HUE032919T2 (pt)
IL (1) IL236917A (pt)
LT (1) LT2877177T (pt)
MA (1) MA37866B1 (pt)
MX (1) MX363605B (pt)
MY (1) MY183398A (pt)
NZ (1) NZ705253A (pt)
PL (1) PL2877177T3 (pt)
PT (1) PT2877177T (pt)
RS (1) RS55646B1 (pt)
RU (1) RU2640046C2 (pt)
SI (1) SI2877177T1 (pt)
TN (1) TN2015000034A1 (pt)
UA (1) UA116107C2 (pt)
WO (1) WO2014016433A1 (pt)
ZA (1) ZA201501209B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS57221B2 (sr) 2008-10-22 2020-08-31 Array Biopharma Inc Jedinjenja supstituisanog pirazolo[1,5-]pirimidina kao inhibitori trk kinaze
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
RU2735545C2 (ru) 2010-05-20 2020-11-03 Эррэй Биофарма Инк. Макроциклические соединения в качестве ингибиторов киназы trk
EP2689778A1 (en) * 2012-07-27 2014-01-29 Pierre Fabre Medicament Derivatives of azaindoles or diazaindoles for treating pain
WO2015143652A1 (en) * 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
CN107106546A (zh) 2014-10-06 2017-08-29 弗拉特利发现实验室有限责任公司 ***并吡啶化合物和用于治疗囊性纤维化的方法
SG11201703962XA (en) 2014-11-16 2017-06-29 Array Biopharma Inc Crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
WO2016096709A1 (en) 2014-12-16 2016-06-23 Eudendron S.R.L. Heterocyclic derivatives modulating activity of certain protein kinases
RU2744852C2 (ru) 2015-10-26 2021-03-16 Локсо Онколоджи, Инк. Точечные мутации в устойчивых к ингибитору trk злокачественных опухолях и связанные с ними способы
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
KR102400423B1 (ko) 2016-04-04 2022-05-19 록쏘 온콜로지, 인코포레이티드 (s)-n-(5-((r)-2-(2,5-디플루오로페닐)-피롤리딘-1-일)-피라졸로[1,5-a]피리미딘-3-일)-3-하이드록시피롤리딘-1-카복사미드의 액체 제형
LT3800189T (lt) 2016-05-18 2023-10-10 Loxo Oncology, Inc. (s)-n-(5-((r)-2-(2,5-difluorfenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3- il)-3-hidroksipirolidin-1-karboksamido gavimas
WO2018049271A1 (en) * 2016-09-09 2018-03-15 Flx Bio, Inc. Chemokine receptor modulators and uses thereof
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
WO2018079759A1 (ja) * 2016-10-31 2018-05-03 塩野義製薬株式会社 TrkA阻害活性を有する縮合複素環および縮合炭素環誘導体
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
WO2019212256A1 (ko) * 2018-05-02 2019-11-07 제이더블유중외제약 주식회사 신규한 헤테로 사이클 유도체
KR102129114B1 (ko) * 2018-07-26 2020-07-02 주식회사 온코파마텍 TrkA 저해 활성을 갖는 화합물 및 이를 유효성분으로 함유하는 통증의 예방 또는 치료용 약학적 조성물
EP3725777A1 (en) * 2019-04-17 2020-10-21 Rottapharm Biotech S.r.l. Benzo- and pyrido-pyrazoles as protein kinase inhibitors
CN110105356B (zh) * 2019-05-31 2022-04-01 四川国康药业有限公司 一种氮杂吲哚类化合物及其制备方法和用途
CN110935250A (zh) 2019-12-10 2020-03-31 科沃斯机器人股份有限公司 空气净化设备

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69815317T2 (de) * 1997-03-19 2005-04-07 Abbott Gmbh & Co. Kg Pyrrolo[2,3-d]pyrimidine und ihre verwendung als tyrosinkinase-inhibitoren
EP1215208B1 (en) 1997-10-27 2006-07-12 Agouron Pharmaceuticals, Inc. 4-Aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases
ATE272626T1 (de) 2000-06-22 2004-08-15 Pfizer Verfahren zur herstellung von pyrazolopyrimidinonen
SE0301906D0 (sv) * 2003-06-26 2003-06-26 Astrazeneca Ab New compounds
DE102004061288A1 (de) * 2004-12-14 2006-06-29 Schering Ag 3-Amino-Pyrazolo[3,4b]pyridine als Inhibitoren von Proteintyrosinkinasen, deren Herstellung und Verwendung als Arzneimittel
BRPI0614884A2 (pt) * 2005-08-25 2011-04-19 Hoffmann La Roche inibidores de p38 map cinase e métodos para uso dos mesmos
US20100056516A1 (en) 2006-07-17 2010-03-04 Williams Peter D 1-hydroxy naphthyridine compounds as anti-hiv agents
PL2120932T3 (pl) 2006-12-20 2015-02-27 Nerviano Medical Sciences Srl Indazolowe pochodne jako inhibitory kinazy do leczenia raka
WO2008089307A2 (en) * 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer
WO2008112695A2 (en) * 2007-03-12 2008-09-18 Irm Llc Pyrazolo [3,4-d] pyrimidines and 1, 2, 5, 6-tetraaza- as- indacenes as protein kinase inhibitors for cancer treatment
CA2693901C (en) * 2007-07-20 2015-12-29 Nerviano Medical Sciences S.R.L. Substituted indazole derivatives active as kinase inhibitors
US8354399B2 (en) * 2008-12-18 2013-01-15 Nerviano Medical Sciences S.R.L. Substituted indazole derivatives active as kinase inhibitors
FR2970967B1 (fr) * 2011-01-27 2013-02-15 Pf Medicament Derives de type azaindazole ou diazaindazole comme medicament
EP2689778A1 (en) * 2012-07-27 2014-01-29 Pierre Fabre Medicament Derivatives of azaindoles or diazaindoles for treating pain

Also Published As

Publication number Publication date
AU2013294920A1 (en) 2015-03-12
HK1207302A1 (en) 2016-01-29
MX363605B (es) 2019-03-26
KR20150038295A (ko) 2015-04-08
NZ705253A (en) 2017-05-26
HRP20170104T1 (hr) 2017-03-24
EP2877177B1 (en) 2016-10-26
CA2879595A1 (en) 2014-01-30
US9381195B2 (en) 2016-07-05
RU2640046C2 (ru) 2017-12-26
JP6456823B2 (ja) 2019-01-23
CY1118478T1 (el) 2017-07-12
MX2015001009A (es) 2015-06-04
MA37866A1 (fr) 2016-05-31
EP2877177A1 (en) 2015-06-03
AU2013294920B2 (en) 2017-08-24
BR112015001502A2 (pt) 2017-07-04
PL2877177T3 (pl) 2017-04-28
RU2015106434A (ru) 2016-09-20
MY183398A (en) 2021-02-18
HUE032919T2 (hu) 2017-11-28
IL236917A (en) 2016-11-30
RS55646B1 (sr) 2017-06-30
WO2014016433A1 (en) 2014-01-30
DK2877177T3 (en) 2017-02-06
TN2015000034A1 (en) 2016-06-29
EP2689778A1 (en) 2014-01-29
MA37866B1 (fr) 2016-12-30
CN104684554B (zh) 2017-05-10
JP2019031542A (ja) 2019-02-28
LT2877177T (lt) 2017-01-25
KR102120505B1 (ko) 2020-06-08
CA2879595C (en) 2020-07-28
JP6732855B2 (ja) 2020-07-29
UA116107C2 (uk) 2018-02-12
US20150190394A1 (en) 2015-07-09
SI2877177T1 (sl) 2017-02-28
BR112015001502B1 (pt) 2023-03-07
JP2015522650A (ja) 2015-08-06
ZA201501209B (en) 2016-03-30
CN104684554A (zh) 2015-06-03
ES2612349T3 (es) 2017-05-16

Similar Documents

Publication Publication Date Title
HK1207302A1 (en) Derivatives of azaindazole or diazaindazole type for treating pain
HUS1900040I1 (hu) Makrociklusos származékok proliferatív betegségek kezelésére
HRP20180939T1 (hr) Kombinirana terapija za liječenje multiple skleroze
EP3025716A4 (en) SUBSTANCE FOR TREATING OR TREATING PAIN
IL234813A0 (en) Methods for increasing the efficacy of cd37-based therapy
EP2897607A4 (en) BETA-HYDROLASE INHIBITORS FOR THE TREATMENT OF CANCER
IL233493A (en) Imidazopyridine derivatives for cancer treatment
IL236870B (en) History of hydroxystatin for the treatment of osteoarthritis
HK1206633A1 (en) Composition for treatment of warts
IL237229A0 (en) Methods of treating cancer using lipoplatin
FI3473276T3 (fi) Tekniikoita paiseiden hoitoon
GB201221118D0 (en) Methods of treatment
GB201216740D0 (en) Methods of treatment
GB201216748D0 (en) Methods of treatment
GB201206324D0 (en) Methods of treatment
GB201206326D0 (en) Methods of treatment
GB201206330D0 (en) Methods of treatment
GB201206325D0 (en) Methods of treatment